Cerebral Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cerebral aneurysm markets are expected to exhibit a CAGR of 7.06% during 2024-2034.
The cerebral aneurysm market has been comprehensively analyzed in IMARC's new report titled "Cerebral Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A cerebral aneurysm, also known as an intracranial or brain aneurysm, is an abnormal bulging or ballooning in the wall of a blood vessel within the brain. These may vary in size and shape, ranging from small and unruptured to large and potentially life-threatening. Unruptured aneurysms often do not cause symptoms, but if they grow larger or press on surrounding structures, they can lead to localized headaches, eye pain or vision changes, dilated pupils, facial pain, cranial nerve dysfunction, etc. On the other hand, a ruptured cerebral aneurysm can result in a sudden, severe headache, neck pain or stiffness, nausea and vomiting, sensitivity to light, changes in mental status or consciousness, seizures, etc. The diagnosis of a cerebral aneurysm typically involves a combination of medical history evaluation, physical examination, and imaging studies. Numerous imaging techniques, such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), cerebral angiography, etc., are commonly used to visualize the blood vessels in the brain and identify an aneurysm. Additional diagnostic tests, including lumbar punctures and neurological assessments, may be performed to evaluate the presence of subarachnoid hemorrhage or associated neurological deficits.
The increasing cases of weakening or thinning of the arterial walls in the brain, which create a bulging or ballooning of the blood vessel, are primarily driving the cerebral aneurysm market. In addition to this, the rising incidence of several associated risk factors, including advancing age, high blood pressure, head trauma, coexisting medical conditions like arteriovenous malformations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiplatelet medications, such as aspirin and clopidogrel, to prevent platelets from clumping together and forming blood clots is further bolstering the market growth. Apart from this, the inflating application of intrasaccular devices, including flow disruptors and embolic coils with complex shapes, for promoting blood clotting and occluding the aneurysm sac in order to reduce the likelihood of rupture is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in imaging technology, such as the introduction of high-resolution 3D rotational angiography and cone-beam CT, which provide detailed anatomical information and aid in treatment planning, are expected to drive the cerebral aneurysm market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cerebral aneurysm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cerebral aneurysm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral aneurysm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cerebral aneurysm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cerebral aneurysm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cerebral aneurysm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the cerebral aneurysm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cerebral aneurysm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cerebral aneurysm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cerebral aneurysm across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral aneurysm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral aneurysm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cerebral aneurysm across the seven major markets?
What is the size of the cerebral aneurysm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cerebral aneurysm?
What will be the growth rate of patients across the seven major markets?
Cerebral Aneurysm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cerebral aneurysm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral aneurysm market?
What are the key regulatory events related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by status related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by phase related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by route of administration related to the cerebral aneurysm market?
The cerebral aneurysm market has been comprehensively analyzed in IMARC's new report titled "Cerebral Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A cerebral aneurysm, also known as an intracranial or brain aneurysm, is an abnormal bulging or ballooning in the wall of a blood vessel within the brain. These may vary in size and shape, ranging from small and unruptured to large and potentially life-threatening. Unruptured aneurysms often do not cause symptoms, but if they grow larger or press on surrounding structures, they can lead to localized headaches, eye pain or vision changes, dilated pupils, facial pain, cranial nerve dysfunction, etc. On the other hand, a ruptured cerebral aneurysm can result in a sudden, severe headache, neck pain or stiffness, nausea and vomiting, sensitivity to light, changes in mental status or consciousness, seizures, etc. The diagnosis of a cerebral aneurysm typically involves a combination of medical history evaluation, physical examination, and imaging studies. Numerous imaging techniques, such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), cerebral angiography, etc., are commonly used to visualize the blood vessels in the brain and identify an aneurysm. Additional diagnostic tests, including lumbar punctures and neurological assessments, may be performed to evaluate the presence of subarachnoid hemorrhage or associated neurological deficits.
The increasing cases of weakening or thinning of the arterial walls in the brain, which create a bulging or ballooning of the blood vessel, are primarily driving the cerebral aneurysm market. In addition to this, the rising incidence of several associated risk factors, including advancing age, high blood pressure, head trauma, coexisting medical conditions like arteriovenous malformations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiplatelet medications, such as aspirin and clopidogrel, to prevent platelets from clumping together and forming blood clots is further bolstering the market growth. Apart from this, the inflating application of intrasaccular devices, including flow disruptors and embolic coils with complex shapes, for promoting blood clotting and occluding the aneurysm sac in order to reduce the likelihood of rupture is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in imaging technology, such as the introduction of high-resolution 3D rotational angiography and cone-beam CT, which provide detailed anatomical information and aid in treatment planning, are expected to drive the cerebral aneurysm market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cerebral aneurysm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cerebral aneurysm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral aneurysm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cerebral aneurysm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cerebral aneurysm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cerebral aneurysm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the cerebral aneurysm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cerebral aneurysm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cerebral aneurysm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cerebral aneurysm across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral aneurysm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral aneurysm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cerebral aneurysm across the seven major markets?
What is the size of the cerebral aneurysm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cerebral aneurysm?
What will be the growth rate of patients across the seven major markets?
Cerebral Aneurysm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cerebral aneurysm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral aneurysm market?
What are the key regulatory events related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by status related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by phase related to the cerebral aneurysm market?
What is the structure of clinical trial landscape by route of administration related to the cerebral aneurysm market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CEREBRAL ANEURYSM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CEREBRAL ANEURYSM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CEREBRAL ANEURYSM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CEREBRAL ANEURYSM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CEREBRAL ANEURYSM - UNMET NEEDS
10 CEREBRAL ANEURYSM - KEY ENDPOINTS OF TREATMENT
11 CEREBRAL ANEURYSM - MARKETED PRODUCTS
11.1 List of Cerebral Aneurysm Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CEREBRAL ANEURYSM - PIPELINE DRUGS
12.1 List of Cerebral Aneurysm Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CEREBRAL ANEURYSM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CEREBRAL ANEURYSM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CEREBRAL ANEURYSM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cerebral Aneurysm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cerebral Aneurysm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cerebral Aneurysm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cerebral Aneurysm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cerebral Aneurysm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cerebral Aneurysm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cerebral Aneurysm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cerebral Aneurysm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cerebral Aneurysm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cerebral Aneurysm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cerebral Aneurysm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cerebral Aneurysm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cerebral Aneurysm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cerebral Aneurysm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cerebral Aneurysm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cerebral Aneurysm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cerebral Aneurysm - Access and Reimbursement Overview
16 CEREBRAL ANEURYSM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CEREBRAL ANEURYSM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CEREBRAL ANEURYSM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CEREBRAL ANEURYSM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CEREBRAL ANEURYSM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CEREBRAL ANEURYSM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CEREBRAL ANEURYSM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CEREBRAL ANEURYSM - UNMET NEEDS
10 CEREBRAL ANEURYSM - KEY ENDPOINTS OF TREATMENT
11 CEREBRAL ANEURYSM - MARKETED PRODUCTS
11.1 List of Cerebral Aneurysm Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CEREBRAL ANEURYSM - PIPELINE DRUGS
12.1 List of Cerebral Aneurysm Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CEREBRAL ANEURYSM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CEREBRAL ANEURYSM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CEREBRAL ANEURYSM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cerebral Aneurysm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cerebral Aneurysm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cerebral Aneurysm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cerebral Aneurysm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cerebral Aneurysm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cerebral Aneurysm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cerebral Aneurysm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cerebral Aneurysm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cerebral Aneurysm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cerebral Aneurysm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cerebral Aneurysm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cerebral Aneurysm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cerebral Aneurysm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cerebral Aneurysm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cerebral Aneurysm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cerebral Aneurysm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cerebral Aneurysm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cerebral Aneurysm - Access and Reimbursement Overview
16 CEREBRAL ANEURYSM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CEREBRAL ANEURYSM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CEREBRAL ANEURYSM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
